ZyVersa Therapeutics [ZVSA] - Last Close: $0.24
ZyVersa Therapeutics is trending after scoring a pivotal patent.
This morning, news broke that the European Patent Office has approved a patent for one of the biopharma firm's key therapeutics.
The EPO granted a patent covering ZyVersa's Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease.
The company says it expects VAR 200 to advance into its next phase of clinical trials in the fourth quarter.
ZVSA is up 58.3% on the news.
My Take: ZVSA is a long-shot biotech stock, but it could have some upside if it can successfully bring VAR 200 to market.
T2 Biosystems [TTOO] - Last Close: $0.083
The Smart Money is taking an interest in T2 Bio.
After Thursday's close, regulatory filings revealed that CR Group LP has taken a substantial position in the struggling biotech stock.
According to the disclosure, CR Group purchased roughly 48 million shares of TTOO common stock on July 3rd.
The firm now controls more than 10% of T2 Bio, and shares are reacting favorably to the news.
TTOO is up 18.9% on active trading volume this morning.
My Take: TTOO has performed terribly over the past six months, but maybe CR Group can help turn the company around. The fact that the firm spent so much money to acquire shares of this company implies that it sees some value here.
